TITLE

Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries

AUTHOR(S)
Brinkhof, Martin W.G.; Dabis, François; Myer, Landon; Bangsberg, David R.; Boulle, Andrew; Nash, Denis; Schechter, Mauro; Laurent, Christian; Keiser, Olivia; May, Margaret; Sprinz, Eduardo; Egger, Matthias; Anglaret 2, Xavier
PUB. DATE
July 2008
SOURCE
Bulletin of the World Health Organization;Jul2008, Vol. 86 Issue 7, p559
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings. Methods Using data on 5491 adult patients starting ART (median age 35 years, 46% female) in 15 treatment programmes in Africa, Asia and South America with ≥ 12 months of follow-up, we investigated risk factors for no follow-up after treatment initiation, and loss to follow-up or death in the first 6 months. Findings Overall, 211 patients (3.8%) had no follow-up, 880 (16.0%) were lost to follow-up and 141 (2.6%) were known to have died in the first 6 months. The probability of no follow-up was higher in 2003-2004 than in 2000 or earlier (odds ratio, OR: 5.06; 95% confidence interval, CI: 1.28-20.0), as was loss to follow-up (hazard ratio, HR: 7.62; 95% CI: 4.55-12.8) but not recorded death (HR: 1.02; 95% CI: 0.44-2.36). Compared with a baseline CD4-cell count ≥ 50 cells/μl, a count < 25 cells/μl was associated with a higher probability of no follow-up (OR: 2.49; 95% CI: 1.43-4.33), loss to follow-up (HR: 1.48; 95% CI: 1.23-1.77) and death (HR: 3.34; 95% CI: 2.10-5.30). Compared to free treatment, fee-for-service programmes were associated with a higher probability of no follow-up (OR: 3.71; 95% CI: 0.97-16.05) and higher mortality (HR: 4.64; 95% CI: 1.11-19.41). Conclusion Early patient losses were increasingly common when programmes were scaled up and were associated with a fee for service and advanced immunodeficiency at baseline. Measures to maximize ART programme retention are required in resource-poor countries.
ACCESSION #
33056673

 

Related Articles

  • Study finds intensive coaching improves antiretroviral therapy adherence.  // American Journal of Health-System Pharmacy;9/1/2002, Vol. 59 Issue 17, p1600 

    The article examines a study by researchers at the University of Buffalo (UB) that found a sharp decrease in viral load among newly diagnosed HIV-positive patients who received intensive medication-adherence coaching from pharmacists in the first 16 weeks of therapy. The study showed that an...

  • Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Moatti, J. P.; N’Doye, I; Hammer, S. M.; Hale, P.; Kazatchkine, M. // Nature Medicine;Dec2003, Vol. 9 Issue 12, p1449 

    Focuses on the attainable paradigm for antiretroviral (ARV) treatment for HIV infection in developing countries. Feasibility of accessing to antiretroviral treatment; Scarcity of the evidence of the impact of the distribution of ARVs on HIV-related risk behaviors; Motivations for attending...

  • Developing good HIV practices in PNG: the Serendipity Educational Endowment Fund (SEFF). Reid, Elizabeth // HIV Australia;2008, Vol. 8 Issue 2, p24 

    The article focuses on the Serendipity Educational Endowment Fund (SEEF), an organization in Papua New Guinea (PNG) that was established to address the issues concerning children whose parents are diagnosed with HIV. It provides an overview of how SEEF was developed and established. It also...

  • From the Executive. Conradie, Francesca // Southern African Journal of HIV Medicine;2014, Vol. 15 Issue 1, p5 

    The article offers the author's insights regarding her experience being an HIV clinician and various HIV treatment program worldwide. Topics discussed include their administration of antiretrovirals (ARVs) where she passed the HIV Management Diploma examination, the ARV programs provided in...

  • Understanding Treatment Refusal Among Adults Presenting for HIV-Testing in Soweto, South Africa: A Qualitative Study. Katz, Ingrid; Dietrich, Janan; Tshabalala, Gugu; Essien, Thandekile; Rough, Kathryn; Wright, Alexi; Bangsberg, David; Gray, Glenda; Ware, Norma // AIDS & Behavior;Apr2015, Vol. 19 Issue 4, p704 

    HIV treatment initiatives have focused on increasing access to antiretroviral therapy (ART). There is growing evidence, however, that treatment availability alone is insufficient to stop the epidemic. In South Africa, only one third of individuals living with HIV are actually on treatment....

  • Hungering for HAART. Montaner, Julio S. G.; Hogg, Robert S. // Annals of Internal Medicine;4/17/2007, Vol. 146 Issue 8, p609 

    The author assesses the South Africa's government-funded highly active antiretroviral therapy (HAART) programs for patients with human immunodeficiency virus (HIV) infection. He states that the slow pace in implementing such programs has been a growing concern of the country. He suggests that...

  • THE HIV DISBELIEVER. France, David // Newsweek (Atlantic Edition);08/28/2000 (Atlantic Edition), Vol. 136 Issue 9, p54 

    Focuses on Christine Maggiore, who heads Alive & Well AIDS Alternatives in Burbank, California. View that HIV does not cause AIDS; Support for her activism against the use of AIDS medications, including South African President Thabo Mbeki; Influence of virologist Peter Duesberg who believes...

  • Weight Change After Antiretroviral Therapy and Mortality. Yuh, Bianca; Tate, Janet; Butt, Adeel A.; Crothers, Kristina; Freiberg, Matthew; Leaf, David; Logeais, Mary; Rimland, David; Rodriguez-Barradas, Maria C.; Ruser, Christopher; Justice, Amy C. // Clinical Infectious Diseases;Jun2015, Vol. 60 Issue 12, p1852 

    Background: Weight gain after antiretroviral therapy (ART) initiation is common, but its implication for mortality is unknown. We evaluated weight change in the first year after ART initiation and its association with subsequent mortality. Methods: Human immunodeficiency virus-infected patients...

  • Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3. Manosuthi, Weerawat; Chimsuntorn, Sukanya; Likanonsakul, Sirirat; Sungkanuparph, Somnuek // AIDS Research & Therapy;2007, Vol. 4, p1 

    Background: Antiretroviral therapy (ART) with a generic fixed-dose combination (FDC) of tavudine (d4T)/lamivudine 3TC)/nevirapine (NVP) is widely used in developing countries. The clinical data of this FDC among very advanced HIV-infected patients is limited. Methods: A retrospective cohort...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics